The FDA has approved a new treatment — Inspire Upper Airway
Stimulation therapy — for patients with moderate-to-severe
obstructive sleep apnea who cannot use a continuous positive airway
The device is implanted in the upper chest, senses breathing patterns,
and mildly stimulates the airway muscles, keeping the airway open. The
device is turned on and off using a handheld remote.
In a study published in the New England Journal of Medicine, some 125
patients (83% men, mean age: 55 years) had the device implanted. At 12
months, the number of apnea events per hour decreased by 68% and
oxygen desaturation events decreased by 70%.
The procedure to implant the device has a shorter recovery time than
surgery to alter airway or facial anatomy, according to the
manufacturer. It is expected to be available to patients by the end of